Activation of Blood Coagulation in Two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk
暂无分享,去创建一个
E. Berti | P. Bucciarelli | A. Marzano | R. Asero | M. Cugno | A. Tedeschi | A. Borghi | S. Griffini | L. Venegoni | E. Grovetti
[1] Michihiro Hide,et al. The EAACI/GA 2 LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update , 2015 .
[2] J. Blalock,et al. Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid , 2014, The Journal of investigative dermatology.
[3] T. Zuberbier,et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. , 2014, Allergy.
[4] R. Asero,et al. Chronic urticaria and coagulation: pathophysiological and clinical aspects , 2014, Allergy.
[5] J. Sheikh,et al. The diagnosis and management of acute and chronic urticaria: 2014 update. , 2014, The Journal of allergy and clinical immunology.
[6] M. Greaves. Pathology and classification of urticaria. , 2014, Immunology and allergy clinics of North America.
[7] S. Saini. Chronic spontaneous urticaria: etiology and pathogenesis. , 2014, Immunology and allergy clinics of North America.
[8] Enno Schmidt,et al. Emerging treatments for pemphigoid diseases. , 2013, Trends in molecular medicine.
[9] R. Wolf,et al. Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. , 2013, Clinics in dermatology.
[10] D. Zillikens,et al. Pemphigoid diseases , 2013, The Lancet.
[11] A. Marzano,et al. Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease , 2013, Clinical and experimental immunology.
[12] A. Marzano,et al. Hypereosinophilic syndrome, Churg-Strauss syndrome and parasitic diseases: possible links between eosinophilia and thrombosis. , 2012, Current vascular pharmacology.
[13] T. van der Poll,et al. Crosstalk between inflammation and coagulation: the lessons of sepsis. , 2012, Current vascular pharmacology.
[14] P. Courville,et al. Incidence and mortality of bullous pemphigoid in France. , 2012, The Journal of investigative dermatology.
[15] T. Dainichi,et al. Lesional Th17 cells and regulatory T cells in bullous pemphigoid , 2011, Experimental dermatology.
[16] D. Fanoni,et al. Activation of coagulation in bullous pemphigoid and other eosinophil‐related inflammatory skin diseases , 2011, Clinical and experimental immunology.
[17] Sudha Xirasagar,et al. Increased Risk of Stroke in Patients With Bullous Pemphigoid: A Population-Based Follow-Up Study , 2011, Stroke.
[18] A. Marzano,et al. Plasma levels of matrix metalloproteinase‐9 in chronic urticaria patients correlate with disease severity and C‐reactive protein but not with circulating histamine‐releasing factors , 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[19] H. Shimizu,et al. What’s new in bullous pemphigoid , 2010, The Journal of dermatology.
[20] F. Ingegnoli,et al. Anti-tumour necrosis factor alpha therapy normalises fibrinolysis impairment in patients with active rheumatoid arthritis , 2010 .
[21] P. Meroni,et al. Skin autoimmunity and blood coagulation , 2010, Autoimmunity.
[22] D. Fanoni,et al. Activation of blood coagulation in bullous pemphigoid: role of eosinophils, and local and systemic implications , 2009, The British journal of dermatology.
[23] A. Pesenti,et al. Tight glycemic control may favor fibrinolysis in patients with sepsis* , 2009, Critical care medicine.
[24] D. Fanoni,et al. Expression of Tissue Factor by Eosinophils in Patients with Chronic Urticaria , 2008, International Archives of Allergy and Immunology.
[25] R. Asero,et al. Severe chronic urticaria is associated with elevated plasma levels of D‐dimer , 2007, Allergy.
[26] F. Rosendaal,et al. Venous thrombosis in the elderly , 2007, Journal of thrombosis and haemostasis : JTH.
[27] D. Fanoni,et al. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. , 2007, The Journal of allergy and clinical immunology.
[28] B. Engelmann,et al. bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use only. , 2006 .
[29] R. Franchis,et al. Antibodies to tissue‐type plasminogen activator (t‐PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t‐PA and possible implications in thrombosis , 2006, Journal of thrombosis and haemostasis : JTH.
[30] R. Eming,et al. T cell control in autoimmune bullous skin disorders. , 2006, The Journal of clinical investigation.
[31] R. Asero,et al. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. , 2006, The Journal of allergy and clinical immunology.
[32] M. Inaoki,et al. Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases , 2006, Archives of Dermatological Research.
[33] T. van der Poll,et al. Two-way interactions between inflammation and coagulation. , 2005, Trends in cardiovascular medicine.
[34] J. Roujeau,et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. , 2005, Archives of dermatology.
[35] K. Yancey. The pathophysiology of autoimmune blistering diseases. , 2005, The Journal of clinical investigation.
[36] E. Sabo,et al. Increased plasma levels of matrix metalloproteinase‐9 are associated with the severity of chronic urticaria , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[37] S. Opal. Phylogenetic and functional relationships between coagulation and the innate immune response. , 2000, Critical care medicine.
[38] P. Amerio,et al. A Th2-like Cytokine Response is Involved in Bullous Pemphigoid. The Role of IL-4 and IL-5 in the Pathogenesis of the Disease , 1999, International journal of immunopathology and pharmacology.
[39] J. Kinet,et al. Assessment of autoimmunity in patients with chronic urticaria. , 1997, The Journal of allergy and clinical immunology.
[40] J. Maraganore,et al. Thrombin functions as an inflammatory mediator through activation of its receptor , 1996, The Journal of experimental medicine.
[41] M. Peters,et al. Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins. , 1996, The American journal of pathology.
[42] J. Kochan,et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. , 1993, The New England journal of medicine.
[43] F. Gong,et al. Thrombin and bradykinin initiate discrete endothelial solute permeability mechanisms. , 1993, The American journal of physiology.
[44] M. Greaves,et al. Detection of circulating histamine releasing autoantibodies with functional properties of anti‐IgE in chronic urticaria , 1991, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[45] A. Kaplan,et al. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. , 1988, The Journal of investigative dermatology.
[46] C. Kennedy,et al. A serological mediator in chronic idiopathic urticaria—a clinical, immunological and histological evaluation , 1986, The British journal of dermatology.
[47] F. Ingegnoli,et al. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. , 2010, Clinical and experimental rheumatology.
[48] R. Asero,et al. Plasma of chronic urticaria patients shows signs of thrombin generation , 2006 .
[49] R. Paul,et al. Thrombin-induced force development in vascular endothelial cells: contribution to alteration of permeability mediated by calcium-dependent and -independent pathways. , 2005, Journal of pharmacological sciences.